Sun sees brighter outlook, seeks new generic Doxil markets
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries reported sales and profit growth in excess of 50% for the second quarter ended 30 September as the performance of its businesses "exceeded plans", and the firm has revised upwards its full year revenue growth guidance to 25% from 18-20% previously.